Market Place
Sourcing Support
Shionogi says Phase 3 study showed COVID pill reduces transmission
30 Oct 2024 //
REUTERS
Zuranolone to face challenges in Japan’s MDD market
21 Oct 2024 //
EXPRESSPHARMA
ViiV Shows 99% Effectiveness For Apretude In HIV PrEP At IDWeek 2024
16 Oct 2024 //
BUSINESSWIRE
Shionogi Presents Real-World Evidence Study Of Cefiderocol At IDWeek
16 Oct 2024 //
BUSINESSWIRE
ViiV Healthcare To Triples Supply Of Long-Acting HIV PrEP
07 Oct 2024 //
BUSINESSWIRE
Shionogi Presents Key Data at IDWeek 2024 on Infectious Disease Advancements
04 Sep 2024 //
BUSINESSWIRE
Shionogi Updates Zatolmilast Study Protocol For Fragile X Syndrome
18 Jul 2024 //
BUSINESSWIRE
Japan`s Shionogi inks €400 M deal with French firm Cilcare
10 Jun 2024 //
BIOSPECTRUM ASIA
Shionogi Expands Infectious Disease Ops To US For Emerging Threats
03 Jun 2024 //
BUSINESSWIRE
Japan`s Shionogi says COVID treatment did not meet endpoint in late-stage trial
13 May 2024 //
REUTERS
Maze lands new partner for Pompe drug, after Sanofi pact came apart
11 May 2024 //
BIOPHARMADIVE
Shionogi, Maze Pompe Disease Candidate MZE001 Deal
10 May 2024 //
BUSINESSWIRE
$10.8M For Malaria, NTD Drugs At Partners Like Shionogi
09 May 2024 //
PR NEWSWIRE
GHIT Fund invests Y1.54bn in malaria and NTD drug projects
09 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Akili Amends Shionogi Deal, Shifts Strategy, Sets Q1 Results Date
30 Apr 2024 //
BUSINESSWIRE
ESCMID 2024: Shionogi Presents Fetcroja Real-World Efficacy Data
18 Apr 2024 //
BUSINESSWIRE
Taiwan FDA approves Shionogi`s FETROJA
28 Feb 2024 //
BIOSPECTRUM ASIA
Akili Announces Positive Results from Shionogi’s Phase 3 Trial of EndeavorRx
27 Feb 2024 //
BUSINESSWIRE
Akili Announces Results from Phase 3 Trial of Localized Version of EndeavorRx
26 Feb 2024 //
BUSINESSWIRE
Shionogi Announces Phase 3 Data Showing Early Resolution of COVID-19 Symptoms
09 Feb 2024 //
BUSINESSWIRE
Shionogi brings generative AI to conferences with `Warrior` portrait campaign
27 Nov 2023 //
ENDPTS
Japan`s Shionogi establishes JV with US-based Apnimed to treat sleep disorders
03 Nov 2023 //
BIOSPECTRUM ASIA
Apnimed Announces Launch of Joint Venture with Shionogi
31 Oct 2023 //
GLOBENEWSWIRE
F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at TIMM
21 Oct 2023 //
GLOBENEWSWIRE
Shionogi Presents New Ensitrelvir COVID-19 Data Supporting Effectiveness
11 Oct 2023 //
BUSINESSWIRE
Shionogi Presents Evidence Demonstrating Effectiveness of Fetroja
11 Oct 2023 //
BUSINESSWIRE
Zatolmilast Receives Rare Pediatric Disease Designation from the U.S. FDA
27 Sep 2023 //
BUSINESSWIRE
Shionogi Presents New Ensitrelvir Clinical and Real-World Data
18 Sep 2023 //
BUSINESSWIRE
Shionogi and Qpex Continue Commitment to Addressing Needs in Infectious Disease
07 Sep 2023 //
BUSINESSWIRE
Global threat of antibiotic resistance highlighted in film supported by Pfizer
01 Sep 2023 //
#N/A
Seven manufacturers sign sublicence agreements with MPP to produce ensitrelvir
27 Jun 2023 //
INDIANPHARMAPOST
Shionogi Extends Infectious Disease Innovation Platform with Acquisition of Qpex
26 Jun 2023 //
BUSINESSWIRE
Shionogi takes antibiotic maker under its wing in $100M cash buyout
26 Jun 2023 //
ENDPTS
Brii Bio Announces Agreements with Qpex & Acquiring Global Rights for BRII-693
25 Jun 2023 //
PR NEWSWIRE
Shionogi starts Phase I trial of Covid-19 antiviral in Japan
18 May 2023 //
CLINICAL TRIALS ARENA
Shionogi Announces Real-World Evidence Demonstrating the Efficacy of Fetcroja
17 Apr 2023 //
BUSINESSWIRE
Shionogi Receives U.S. FDA Fast Track Designation for Ensitrelvir Fumaric Acid
04 Apr 2023 //
BUSINESSWIRE
Shionogi to Present Data Showing COVID-19 Symptom Recurrence is Not Associated with Ensitrelvir Treatment
04 Apr 2023 //
BUSINESSWIRE
GHIT Fund Announces New Investments: A Total of 260 Million Yen in Shionogi
13 Mar 2023 //
PR NEWSWIRE
Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval
27 Feb 2023 //
REUTERS
Shionogi’s Antibiotic, FETCROJA Is Now Available in the Netherlands
22 Feb 2023 //
BUSINESSWIRE
Shionogi Presents Pivotal Ensitrelvir Fumaric Acid Phase 3 Data
21 Feb 2023 //
BUSINESSWIRE
Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program
15 Feb 2023 //
BUSINESSWIRE
U.S. NIH starts trial for Shionogi`s COVID-19 pill
15 Feb 2023 //
REUTERS
Shionogi’s Innovative Antibiotic, FETCROJA, Is Now Available in Denmark
01 Feb 2023 //
BUSINESSWIRE
Shionogi’s Innovative Antibiotic, FETCROJA, Is Now Available in Norway
17 Jan 2023 //
BUSINESSWIRE
Shionogi commences Phase I/II/III and Phase III trials of Covid-19 vaccine
17 Jan 2023 //
CLINICAL TRIALS ARENA
Notice Regarding a License Agreement for the Promotion of Ensitrelvir
29 Dec 2022 //
SHIONOGI
Japanese government buys quantity of COVID-19 drug Xocova from Shionogi
13 Dec 2022 //
BIOSPECTRUMASIA
Kaneka to Manufacture and Supply Intermediates for Shionogi COVID-19 Drug
29 Nov 2022 //
BUSINESSWIRE
Shionogi Announces Corporate Reorganization and Personnel Reassignment
25 Nov 2022 //
PRESS RELEASE
Japan to start wide distribution of first domestic COVID pill next Monday
25 Nov 2022 //
NHK
Xocova Tablets 125mg Approved in Japan for the Treatment of SARS-CoV-2 Infection
22 Nov 2022 //
PRESS RELEASE
Shionogi drug to compete with Paxlovid and Lagevrio in Japan
22 Nov 2022 //
FIERCEPHARMA
SHIONOGI Report 2022 Won Silver Award in WICI Japan Integrated Report Award 2022
21 Nov 2022 //
PRESS RELEASE
Shionogi, Active Citizenship to Address on Antimicrobial Resistance
21 Nov 2022 //
BUSINESSWIRE
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
02 Nov 2022 //
PRESS RELEASE
Notice of Entering Into a Capital Alliance Agreement with LIFESCAPES
02 Nov 2022 //
PRESS RELEASE
OrsoBio Acquires Phase 2-Ready, Selective ACC2 Inhibitor from Shionogi & Co
02 Nov 2022 //
BUSINESSWIRE
Shionogi Presents Real-World Evidence Showing Strong Efficacy with Fetroja
19 Oct 2022 //
BUSINESSWIRE
